, Tracking Stock Market Picks
Enter Symbol:
Alnylam Pharmaceuticals, Inc. (ALNY) [hlAlert]

up 63.95 %

Alnylam Pharmaceuticals, Inc. (ALNY) rated Buy with price target $108 by Deutsche Bank

Posted on: Friday,  Jan 17, 2014  1:25 PM ET by Deutsche Bank

Deutsche Bank rated Buy Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) on 01/17/2014. Previously Deutsche Bank rated Buy Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) on
09/24/2013., when the stock price was $63.98. Since then, Alnylam Pharmaceuticals, Inc. has gained 63.96% as of 01/22/2016's recent price of $104.90.
If you would have followed the previous Deutsche Bank's recommendation on ALNY, you would have gained 63.95% of your investment in 850 days.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.

Deutsche Bank is one of the largest European fund managers. DWS was founded in 1956 and is an integral part of the Asset Management division of Deutsche Bank. This division is one of the largest global asset managers.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/17/2014 1:25 PM Buy
88.47 108.00
as of 10/17/2014
1 Week up  18.29 %
1 Month up  10.92 %
3 Months up  65.66 %
1 YTD up  34.02 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/24/2013 1:25 PM Buy
63.98 80.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy